Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Non-Current AssetsPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Iovance Biotherapeutics (IOVA) Current Leases: 2019-2025

Historic Current Leases for Iovance Biotherapeutics (IOVA) over the last 3 years, with Sep 2025 value amounting to $6.3 million.

  • Iovance Biotherapeutics' Current Leases was N/A to $6.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $6.3 million, marking a year-over-year change of. This contributed to the annual value of $12.9 million for FY2024, which is 65.82% up from last year.
  • Latest data reveals that Iovance Biotherapeutics reported Current Leases of $6.3 million as of Q3 2025, which was down 11.16% from $7.1 million recorded in Q2 2025.
  • Iovance Biotherapeutics' Current Leases' 5-year high stood at $12.9 million during Q4 2024, with a 5-year trough of $6.3 million in Q3 2025.
  • Its 3-year average for Current Leases is $9.7 million, with a median of $10.5 million in 2023.
  • Per our database at Business Quant, Iovance Biotherapeutics' Current Leases soared by 65.82% in 2024 and then fell by 23.28% in 2025.
  • Iovance Biotherapeutics' Current Leases (Quarterly) stood at $7.8 million in 2023, then soared by 65.82% to $12.9 million in 2024, then decreased by 23.28% to $6.3 million in 2025.
  • Its Current Leases was $6.3 million in Q3 2025, compared to $7.1 million in Q2 2025 and $8.5 million in Q1 2025.